Abstract

BackgroundWorld Health Organization recommends a standard daily oral dose of iron and folic acid (IFA) supplements throughout pregnancy to begin as early as possible. The aim of the present study was to determine the prevalence of use of antenatal IFA supplements, and the socio-demographic factors associated with the non-use of antenatal IFA supplements from 14 selected districts in Pakistan.MethodsData was derived from a cross sectional household survey conducted in 14 project districts across Pakistan. Trained female field workers conducted interviews with married women of reproductive age from December 2011 to March 2012. Women with the most recent live births in the preceding five years of the survey were selected for this study. Data was analysed by using STATA 13 and adjusted for the cluster sampling design. Multivariate logistic regression models were constructed to identify the independent factors associated with the non-use of antenatal IFA supplements.ResultsOf 6,266 women interviewed, 2,400 (38.3%, 95% CI, 36.6%, 40.1%) reported taking IFA supplements during their last pregnancy. Among IFA users, the most common source of supplements was doctors (49.4%) followed by community health workers (40.3%). The mean (±SE) number of supplements used was 76.9 (±51.6), and the mean (±SE) month of pregnancy at initiation of supplementation was 5.3 (±1.7) months. Socio-demographic factors significantly associated with the non-use of antenatal IFA supplements were living in Dera Ghazi Khan district (AdjOR: 1.72), maternal age 45 years and above (AdjOR: 1.97), no maternal education (AdjOR: 2.36), no paternal education (AdjOR: 1.58), belonging to the lowest household wealth index quartile (AdjOR: 1.47), and no use of antenatal care (ANC) services (AdjOR: 13.39).ConclusionsThe coverage of antenatal IFA supplements is very low in the surveyed districts of Pakistan, and the lack of parental education, older aged women, belonging to poorest households, residence in Dera Ghazi Khan district and no use of ANC services were all significantly associated with non-use of these supplements. These findings highlight the urgent need to develop interventions targeting all pregnant women by improving ANC coverage to increase the use of antenatal IFA supplements in Pakistan.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2393-14-305) contains supplementary material, which is available to authorized users.

Highlights

  • World Health Organization recommends a standard daily oral dose of iron and folic acid (IFA) supplements throughout pregnancy to begin as early as possible

  • The aim of the current study was to describe the use of antenatal IFA supplements and to identify socio-demographic factors of pregnant women associated with non-use of antenatal IFA supplements in 14 selected districts of Pakistan

  • The low prevalence of the use of antenatal IFA supplements and factors associated with non-use of antenatal IFA supplements are important to provide guidance for the development of evidence based approaches directed at increasing the intake and coverage of antenatal IFA supplementation in Pakistan

Read more

Summary

Introduction

World Health Organization recommends a standard daily oral dose of iron and folic acid (IFA) supplements throughout pregnancy to begin as early as possible. Several studies have reported associations of anaemia during pregnancy with the risk of maternal mortality [4] and poor pregnancy outcomes in terms of low birth weight [5,6,7], and prematurity [5,7,8], which is the leading cause of neonatal mortality in developing countries [9]. To reduce the risk of maternal anaemia, iron deficiency and poor pregnancy outcomes, the World Health Organization (WHO) guidelines recommend a standard daily oral dose of 30-60 mg iron and 400 μg folic acid supplements throughout pregnancy, to begin as early as possible as a part of antenatal care (ANC) programs. Where the prevalence of anaemia in pregnancy is over 40%, a daily dose of 60 mg of elemental iron is preferred over a lower dose of 30 mg [11]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call